We compared the predicted hepatocellular carcinoma probability for individuals with cirrhosis and cured hepatitis C with the general population
This study explores the impact of interferon-free therapies on hepatitis C virus related hepatocellular carcinoma at a population level.
The goal of this study was to quantify the bias in estimating risk of hepatocellular carcinoma for patients with cirrhosis and cured hepatitis C.
We conducted an external validation of six HCC prediction models for UK patients with cirrhosis HCV virological cure.
We examined the impact of the introduction of direct-acting antiviral (DAA) therapies on hepatitis C related decompensated cirrhosis (DC) through analysis of population-based data from Scotland.